- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
The State of Biosimilars in the United States: The Center for Biosimilars® Peer Exchange
The introduction of biosimilars to the US market has led to an unprecedented amount of uncertainty as stakeholders try to understand the implications of their arrival. In the following Peer Exchange discussion from The Center for Biosimilars®, held in September 2017, industry experts discuss regulation, policy, and litigation issues in the world of biosimilars.
The introduction of biosimilars to the US market has led to an unprecedented amount of uncertainty as stakeholders try to understand the implications of their arrival. The Center for Biosimilars®, a sister site of The American Journal of Managed Care®, serves as an online resource that brings together the worlds of clinical, business, regulatory, policy, and economic outcomes of biosimilars.
The introduction of biosimilars to the United States provides great promise, as they are expected to bring down the price of medications, but also challenges. Biosimilars face stringent regulatory requirements, continued education of patients and physicians, and ongoing litigation issues.
In the following Peer Exchange discussion from The Center for Biosimilars®, held in September 2017, industry experts discuss regulation, policy, and litigation issues in the world of biosimilars. For more insight into the world of biosimilar therapies, visit centerforbiosimilars.com.
Listen below or through one of these podcast services:
iTunes: http://apple.co/2eYWTss
TuneIn: http://bit.ly/2gv7iwj
Stitcher: http://bit.ly/2gCqtFg
5 Key Drug Approvals and CRLs in 2024
December 27th 2024In 2024, multiple drugs received complete response letters (CRLs), sometimes unrelated to the safety and efficacy of the drug, but patients with schizophrenia gained the first new treatment with a new mechanism of action in decades.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
From Approval to Practice: Addressing the Hurdles in Biosimilar Integration
December 12th 2024Recent discussions at an Institute for Value-Based Medicine event highlighted the significant potential of biosimilars in reshaping the health care landscape, despite facing considerable barriers to adoption.
Read More
